View older revisions Content changed at 2021-11-23, 1400/09/02

Protocol summary

Study aim
Objective: evaluating the effect of total anthocyanin base standardized (cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde and adiponectin in patients with non-alcoholic fatty liver (NAFLD).
Design
Patients are randomly assigned into 2 groups (n=40 in each group) using a software to receive total anthocyanin base standardized (cornus mas L.) fruit extract (equal to 320 mg/d anthocyanins) or placebo daily for 12 weeks.
Settings and conduct
In a randomized double-blind clinical trial, 80 patients with NAFLD will be recruited from Diabetes Research Center, Shahid Sadoughi university of medical sciences, Yazd. The subjects are randomly divided into two groups to take total anthocyanin base standardized (cornus mas L.) fruit extract or placebo.
Participants/Inclusion and exclusion criteria
Study population: patients with NAFLD (n=80). Inclusion criteria: ALT levels more than 30 U / L in men and more than 19 U / L in women, age 25-26 years, the patients with grade 1, 2 and 3 fatty liver, the consent of subject to participate in the study, the patients are from Yazd. Exclusion criteria: The history of diseases including cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson and cancer; Consumption of medications including corticosteroids, nonsteroidal anti-inflammatory drugs, hypoglycemic agents, tamoxifen, sodium valproate, methotrexate, probiotics, any medicine or supplement that affect liver function, supplements with antioxidant and anti-inflammatory properties; Following a special diet; Pregnancy and breastfeeding; Alcohol consumption.
Intervention groups
Intervention group with total anthocyanin base standardized (cornus mas L.) fruit extract or placebo group.
Main outcome variables
Liver function (liver enzymes and cytokeratin-18 levels, liver steatosis and fibrosis); tumor necrosis factor α, malondealdehyde and adiponectin levels.

General information

Reason for update
A secondary outcome was modified without changing other sections of the protocol.
Acronym
IRCT registration information
IRCT registration number: IRCT20180419039359N1
Registration date: 2018-09-30, 1397/07/08
Registration timing: prospective

Last update: 2021-11-23, 1400/09/02
Update count: 2
Registration date
2018-09-30, 1397/07/08
Registrant information
Name
Zohreh Sadat Sangsefidi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 35 3820 9100
Email address
sangsefidiz@ssu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-12-22, 1397/10/01
Expected recruitment end date
2019-06-22, 1398/04/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The study of effect of total anthocyanin base standardized (cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde and adiponectin in patients with non-alcoholic fatty liver.
Public title
The study of effect of total anthocyanin base standardized (cornus mas L.) fruit extract in patients with non-alcoholic fatty liver
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
ALT levels more than 30 U / L in men and more than 19 U / L in women Age 25-26 years Diagnosis of the disease by ultrasonography and by a gastroenterologist The patients with grade 1, 2 and 3 fatty liver The consent of subject to participate in the study The patients are from Yazd
Exclusion criteria:
The history of diseases including cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson and cancer. Consumption of medications including corticosteroids, nonsteroidal anti-inflammatory drugs, hypoglycemic agents or any medicine that affect blood glucose, tamoxifen, sodium valproate, methotrexate, probiotics, any medicine or supplement that affect liver function, supplements with antioxidant and anti-inflammatory properties (such as vitamin D, vitamin E, omega-3, resveratrol) during 1 month before the study Following a special diet during 1 month before the study Pregnancy and breastfeeding شlcohol consumption
Age
From 25 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Investigator
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization is performed using Random allocation software. Also, randomization is stratified by age gender.
Blinding (investigator's opinion)
Double blinded
Blinding description
The products ((cornus mas L.) fruit extract and placebo) are packed in the bottles that are same in terms of color, shape and size and labeled with "A" and "B" by an outside person who dose not know the details of the study. Therefore, participants and researchers will not be aware of the nature of the products in bottles.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Shahid Sadoughi University of Medical Sciences
Street address
Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences ,Alam Square.
City
Yazd
Province
Yazd
Postal code
8915173160
Approval date
2018-03-17, 1396/12/26
Ethics committee reference number
IR.SSU.SPH.REC.1396.171

2

Ethics committee
Name of ethics committee
Ethics Committee of Shahid Sadoughi University of Medical Sciences
Street address
Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences ,Alam Square.
City
Yazd
Province
Yazd
Postal code
8915173160
Approval date
2021-05-03, 1400/02/13
Ethics committee reference number
IR.SSU.SPH.REC.1400.020

Health conditions studied

1

Description of health condition studied
non-alcoholic fatty liver
ICD-10 code
K76.0
ICD-10 code description
Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description
Serum levels of Alanine Aminotransferase (ALT)
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

2

Description
Serum levels of Aspartate Aminotransaminase (AST)
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

3

Description
Serum levels of Tumor necrosis factor α (TNF-α)
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA kit

4

Description
Serum levels of Malondealdehyde (MDA)
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA kit

5

Description
Serum levels of adiponectin
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA kit

6

Description
Serum levels of cytokeratin-18 fragment M30 (CK-18 M30)
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA kit

7

Description
Liver steatosis
Timepoint
Before and after the 12-week intervention
Method of measurement
By ultrasonography

8

Description
Liver fibrosis
Timepoint
Before and after the 12-week intervention
Method of measurement
By fibroscan

Secondary outcomes

1

Description
Fasting blood glucose (FBS)
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

2

Description
Serum levels of Triglyceride (TG)
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

3

Description
Serum levels of High-density lipoprotein (HDL)
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

4

Description
Serum levels of Low-density lipoprotein (LDL)
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

5

Description
Serum levels of total cholesterol
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

6

Description
Serum levels of insulin
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA kit

7

Description
Insulin resistance
Timepoint
Before and after the 12-week intervention
Method of measurement
By HOMA-IR and QUICKI

8

Description
Lipid accumulation product
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

9

Description
Atherogenic index of plasma
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

10

Description
Atherogenic coefficient
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

11

Description
Castelli 1 index
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

12

Description
Castelli 2 index
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

13

Description
TyG index
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

14

Description
Fatty liver index
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

15

Description
Hepatic steatosis index
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

16

Description
Visceral adiposity index
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

17

Description
NAFLD-liver fat score
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

18

Description
estimated glucose infusion rate
Timepoint
Before and after the 12-week intervention
Method of measurement
Formula

19

Description
Gamma glutamyl transpeptidase
Timepoint
Before and after the 12-week intervention
Method of measurement
By autoanalyzer

20

Description
Serum levels of E-selectin
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA method

21

Description
Serum levels of Asymmetric dimethylarginine
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA method

22

Description
Serum levels of nitric oxide
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA method

23

Description
Seum levels of C reactive protein
Timepoint
Before and after the 12-week intervention
Method of measurement
By ELISA method

Intervention groups

1

Description
Intervention group: Daily intake of total anthocyanin base standardized (cornus mas L.) fruit extract (equal to 320 mg/d anthocyanins) for 12 weeks.
Category
Treatment - Drugs

2

Description
Control group: Daily intake of placebo for 12 weeks.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Diabetes Research Center, Shahid Sadoughi university of medical sciences, Yazd, Iran
Full name of responsible person
Dr. Saeed Hossein Khalilzadeh
Street address
Diabetes Research Center, Alley of Art Hall, Beginning of Bahonar Square to Azadi Square, Shahid Sadoughi Boulevard
City
Yazd
Province
Yazd
Postal code
8915173160
Phone
+98 35 3728 0226
Email
drc@ssu.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Dr. Masoud Mirzaei
Street address
Shahid Sadoughi University of Medical Sciences, Bahonar Square
City
Yazd
Province
Yazd
Postal code
8916978477
Phone
+98 35 3726 3733
Fax
+98 35 3726 3732
Email
masoud_mirzaei@hotmail.com
Web page address
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Yazd University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Zohreh Sadat Sangsefidi
Position
Ph.D. candidate on nutrition
Latest degree
Master
Other areas of specialty/work
Nutrition
Street address
Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Alam Square.
City
Yazd
Province
Yazd
Postal code
8915173160
Phone
+98 353820910014
Fax
+98 35 3820 9119
Email
sangsefidi.zsadat@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Hassan Mozaffari-Khosravi
Position
professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Alam Square.
City
Yazd
Province
Yazd
Postal code
8915173160
Phone
+98 353820910014
Fax
+98 35 3820 9119
Email
mozaffari.kh@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Zohreh Sadat Sangsefidi
Position
PhD candidate on Nutrition
Latest degree
Master
Other areas of specialty/work
Nutrition
Street address
Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Alam Square.
City
Yazd
Province
Yazd
Postal code
8915173160
Phone
+98 35 3820 9100
Fax
+98 35 3820 9119
Email
sangsefidi.zsadat@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...